Is INAB or MGX more profitable?

IN8bio has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -91.18% -76.93% Metagenomi -384.61% -63.65% -44.52%

Which has higher earnings and valuation, IMMP or INAB?

IN8bio has lower revenue, but higher earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $16.40M 2.04 -$53.82M N/A N/A IN8bio N/A N/A -$19.44M -$1.62 N/A

Is IMMP or INAB more profitable?

Prima BioMed's return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A IN8bio N/A -91.18% -76.93%

Does the media prefer IMMP or INAB?

In the previous week, Prima BioMed had 3 more articles in the media than IN8bio. MarketBeat recorded 5 mentions for Prima BioMed and 2 mentions for IN8bio. IN8bio's average media sentiment score of 1.21 beat Prima BioMed's score of 0.39 indicating that IN8bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral IN8bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MCRB or INAB more profitable?

IN8bio has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. IN8bio's return on equity of -91.18% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Seres Therapeutics -1,192.94% -114.82% -34.15% IN8bio N/A -91.18% -76.93%

Does the media favor MCRB or INAB?

In the previous week, Seres Therapeutics and Seres Therapeutics both had 2 articles in the media. Seres Therapeutics' average media sentiment score of 1.27 beat IN8bio's score of 1.21 indicating that Seres Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IN8bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, INAB or EDSA?

Edesa Biotech is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$1.62 N/A Edesa Biotech N/A N/A -$7.19M -$1.69 N/A

Is INAB or EDSA more profitable?

IN8bio's return on equity of -91.18% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -91.18% -76.93% Edesa Biotech N/A -560.22% -105.74%

Do analysts recommend IZTC or INAB?

IN8bio has a consensus price target of $4.00, suggesting a potential upside of 175.86%. Given IN8bio's stronger consensus rating and higher possible upside, analysts plainly believe IN8bio is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, IZTC or INAB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A IN8bio N/A N/A -$19.44M -$1.62 N/A

Is IZTC or INAB more profitable?

Invizyne Technologies' return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A IN8bio N/A -91.18% -76.93%

IN8bio (INAB) Competitors

$1.45 +0.12 (+9.02%)

As of 02:17 PM Eastern

Compare

INAB vs. MGX, IMMP, MCRB, EDSA, and IZTC

Should you buy IN8bio stock or one of its competitors? IN8bio's main competitors and comparable companies include Metagenomi (MGX), Prima BioMed (IMMP), Seres Therapeutics (MCRB), Edesa Biotech (EDSA), and Invizyne Technologies (IZTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does IN8bio compare to Metagenomi?

IN8bio (NASDAQ:INAB) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

IN8bio presently has a consensus target price of $4.00, indicating a potential upside of 175.86%. Metagenomi has a consensus target price of $6.00, indicating a potential upside of 447.95%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

92.1% of IN8bio shares are owned by institutional investors. 14.5% of IN8bio shares are owned by insiders. Comparatively, 12.5% of Metagenomi shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, IN8bio had 1 more articles in the media than Metagenomi. MarketBeat recorded 2 mentions for IN8bio and 1 mentions for Metagenomi. Metagenomi's average media sentiment score of 1.82 beat IN8bio's score of 1.21 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Overall Sentiment
IN8bio	Positive
Metagenomi	Very Positive

IN8bio has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-91.18%	-76.93%
Metagenomi	-384.61%	-63.65%	-44.52%

IN8bio has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

IN8bio has higher earnings, but lower revenue than Metagenomi. IN8bio is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A
Metagenomi	$25.21M	1.64	-$87.87M	-$2.49	N/A

Summary

Metagenomi beats IN8bio on 10 of the 16 factors compared between the two stocks.

How does IN8bio compare to Prima BioMed?

Prima BioMed (NASDAQ:IMMP) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

In the previous week, Prima BioMed had 3 more articles in the media than IN8bio. MarketBeat recorded 5 mentions for Prima BioMed and 2 mentions for IN8bio. IN8bio's average media sentiment score of 1.21 beat Prima BioMed's score of 0.39 indicating that IN8bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
IN8bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prima BioMed's return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
IN8bio	N/A	-91.18%	-76.93%

IN8bio has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$16.40M	2.04	-$53.82M	N/A	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A

Prima BioMed currently has a consensus target price of $110.00, indicating a potential upside of 2,322.91%. IN8bio has a consensus target price of $4.00, indicating a potential upside of 175.86%. Given Prima BioMed's stronger consensus rating and higher probable upside, research analysts plainly believe Prima BioMed is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Prima BioMed has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by company insiders. Comparatively, 14.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Prima BioMed beats IN8bio on 8 of the 12 factors compared between the two stocks.

How does IN8bio compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Seres Therapeutics has higher revenue and earnings than IN8bio. Seres Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	38.10	$5.70M	-$2.43	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A

Seres Therapeutics presently has a consensus price target of $17.00, suggesting a potential upside of 467.61%. IN8bio has a consensus price target of $4.00, suggesting a potential upside of 175.86%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Seres Therapeutics is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Seres Therapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market. Comparatively, IN8bio has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

IN8bio has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. IN8bio's return on equity of -91.18% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
IN8bio	N/A	-91.18%	-76.93%

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by insiders. Comparatively, 14.5% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Seres Therapeutics and Seres Therapeutics both had 2 articles in the media. Seres Therapeutics' average media sentiment score of 1.27 beat IN8bio's score of 1.21 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IN8bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Seres Therapeutics and IN8bio tied by winning 7 of the 14 factors compared between the two stocks.

How does IN8bio compare to Edesa Biotech?

IN8bio (NASDAQ:INAB) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

92.1% of IN8bio shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 14.5% of IN8bio shares are held by insiders. Comparatively, 24.4% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

IN8bio's return on equity of -91.18% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-91.18%	-76.93%
Edesa Biotech	N/A	-560.22%	-105.74%

IN8bio currently has a consensus target price of $4.00, indicating a potential upside of 175.86%. Edesa Biotech has a consensus target price of $5.00, indicating a potential upside of 24.84%. Given IN8bio's higher probable upside, equities research analysts clearly believe IN8bio is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Edesa Biotech is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A

IN8bio has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

In the previous week, IN8bio had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 2 mentions for IN8bio and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.79 beat IN8bio's score of 1.21 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
IN8bio	Positive
Edesa Biotech	Very Positive

Summary

IN8bio beats Edesa Biotech on 7 of the 13 factors compared between the two stocks.

How does IN8bio compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

92.1% of IN8bio shares are held by institutional investors. 14.5% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, IN8bio had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for IN8bio and 0 mentions for Invizyne Technologies. IN8bio's average media sentiment score of 1.21 beat Invizyne Technologies' score of 0.00 indicating that IN8bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
IN8bio	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A

IN8bio has a consensus price target of $4.00, suggesting a potential upside of 175.86%. Given IN8bio's stronger consensus rating and higher possible upside, analysts plainly believe IN8bio is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Invizyne Technologies' return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
IN8bio	N/A	-91.18%	-76.93%

Summary

IN8bio beats Invizyne Technologies on 7 of the 9 factors compared between the two stocks.

Get IN8bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INAB vs. The Competition

Export

Metric	IN8bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.30M	$3.90B	$7.13B	$13.11B
Dividend Yield	N/A	3.63%	2.52%	14.40%
P/E Ratio	-0.90	13.65	273.64	25.86
Price / Sales	N/A	1,297.80	656.97	105.97
Price / Cash	N/A	120.99	79.75	52.18
Price / Book	0.51	15.73	10.54	6.28
Net Income	-$19.44M	-$22.67M	$3.50B	$360.95M
7 Day Performance	21.85%	-2.53%	-2.04%	-1.67%
1 Month Performance	33.03%	-8.50%	-5.21%	-3.19%
1 Year Performance	-35.84%	24.12%	10.28%	2.93%

IN8bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INAB IN8bio	3.614 of 5 stars	$1.45 +9.0%	$4.00 +175.9%	-37.3%	$14.30M	N/A	N/A	18	Positive News Gap Up
MGX Metagenomi	4.1438 of 5 stars	$1.15 +3.0%	$6.00 +419.9%	-55.3%	$43.56M	$25.21M	N/A	113	Positive News
IMMP Prima BioMed	3.1374 of 5 stars	$0.29 -2.2%	$5.50 +1,829.8%	-86.7%	$42M	$16.40M	N/A	2,021	News Coverage
MCRB Seres Therapeutics	3.3722 of 5 stars	$4.04 -0.7%	$17.00 +320.7%	-82.6%	$40.61M	$790K	N/A	66	News Coverage Positive News Gap Down
EDSA Edesa Biotech	2.6239 of 5 stars	$4.10 -0.2%	$5.00 +21.9%	+70.4%	$39.53M	N/A	N/A	17	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INAB) was last updated on 10/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IN8bio (INAB) Competitors

INAB vs. MGX, IMMP, MCRB, EDSA, and IZTC

How does IN8bio compare to Metagenomi?

Summary

How does IN8bio compare to Prima BioMed?

Summary

How does IN8bio compare to Seres Therapeutics?

Summary

How does IN8bio compare to Edesa Biotech?

Summary

How does IN8bio compare to Invizyne Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INAB vs. The Competition

IN8bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IN8bio (INAB) Competitors

INAB vs. MGX, IMMP, MCRB, EDSA, and IZTC

How does IN8bio compare to Metagenomi?

Do analysts rate INAB or MGX?

Do institutionals & insiders have more ownership in INAB or MGX?

Does the media refer more to INAB or MGX?

Is INAB or MGX more profitable?

Which has more risk and volatility, INAB or MGX?

Which has stronger earnings and valuation, INAB or MGX?

Summary

How does IN8bio compare to Prima BioMed?

Does the media prefer IMMP or INAB?

Is IMMP or INAB more profitable?

Which has higher earnings and valuation, IMMP or INAB?

Do analysts recommend IMMP or INAB?

Which has more risk and volatility, IMMP or INAB?

Do insiders & institutionals believe in IMMP or INAB?

Summary

How does IN8bio compare to Seres Therapeutics?

Which has better valuation & earnings, MCRB or INAB?

Do analysts rate MCRB or INAB?

Which has more volatility & risk, MCRB or INAB?

Is MCRB or INAB more profitable?

Do insiders and institutionals have more ownership in MCRB or INAB?

Does the media favor MCRB or INAB?

Summary

How does IN8bio compare to Edesa Biotech?

Do insiders and institutionals believe in INAB or EDSA?

Is INAB or EDSA more profitable?

Do analysts prefer INAB or EDSA?

Which has stronger earnings & valuation, INAB or EDSA?

Which has more risk and volatility, INAB or EDSA?

Does the media refer more to INAB or EDSA?

Summary

How does IN8bio compare to Invizyne Technologies?

Do institutionals & insiders hold more shares of IZTC or INAB?

Does the media favor IZTC or INAB?

Which has preferable earnings & valuation, IZTC or INAB?

Do analysts recommend IZTC or INAB?

Is IZTC or INAB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INAB vs. The Competition

IN8bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools